Abstract:Abstract Vascular endothelial growth inhibitor (VEGI, also known as TNFSF15) is an anti-angiogenic cytokine found to be associated with tumour-related vasculature in certain maligancies. Three isoforms, VEGI 251, VEGI192, and VEGI174, have been identified, all sharing a common extracellular domain of 151 C-terminal amino acid sequence critical for biological activity of all three isoforms. Previous studies showed tumor inhibitory effect of truncated recombinant VEGI proteins in breast and colorectal cancer xenograft models, however, the antitumor activity of the full length VEGI molecules have not been well characterized in other malignancies, including kidney neoplasm. The objective of the present study was set to evaluate biological impact of forced expression of full length VEGI-174 in a renal cell carcinoma (RCC) cell line, 786-O, and in 786-O derived xenograft models. We found that Increased VEGI-174 expression in 786-O cells did not affect cell growth and apoptosis in vitro, but did reduce cell adhesion and the ability of endothelial cells to form capillary-like structures in co-culture. Subcutaneous xenograft models were successfully established using the 786-O RCC cells with or without forced expression of VEGI-174. Significantly reduced tumor volume, accompanied by reduced tumor microvessel density and decreased Ki67 and VEGFR2 expression, was observed in animals injected with VEGI-174 transfected 786-O cells compared to those in the control groups. Our results demonstrated that increased expression of full length VEGI-174 in RCC 786-O cells resulted in significant reduction in tumor volume most likely via angiogenic inhibition rather than on tumor growth per se. Despite the lack of antitumor effect of full length VEGI174 in some xenograft tumor models in other studies, our results suggest that antitumor effect of the full length VEGI-174 may be cancer type specific, and VEGI-174 may still be a valuable candidate toward angiogenesis based cancer therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1356. doi:1538-7445.AM2012-1356

Expression and role of vascular endothelial growth inhibitor in sporadic clear cell renal cell carcinoma

Expression of Human Vascular Endothelial Growth Factor in Ampullary Carcinoma and Its Significance

The Differential Expression of Vascular Endothelial Growth Inhibitor Isoforms, VEGI251, VEGI174 and VEGI192 in Human Clear-cell Renal Cell Carcinoma

Vascular Endothelial Growth Inhibitor 174 is a Negative Regulator of Aggressiveness and Microvascular Density in Human Clear Cell Renal Cell Carcinoma.

Suppression of Renal Cell Carcinoma Growth in Vivo by Forced Expression of Vascular Endothelial Growth Inhibitor.

Expression of Vascular Endothelial Growth Factor in Renal Cell Carcinoma and Its Clinical Implications

Vascular Endothelial Growth Inhibitor, a Cytokine of the Tumor Necrosis Factor Family, is Associated With Epithelial-Mesenchymal Transition in Renal Cell Carcinoma.

Relationship between vascular endothelial growth factor and nuclear factor-kappaB in renal cell tumors

[Mutation of Von Hippel-Lindau Gene and Expression of Vascular Endothelial Growth Factor in Sporadic Clear Cell Renal Cell Carcinoma and Their Relationships to Angiogenesis].

The correlation of VEGF expression with MVD in renal pelvic carcinoma and its clinical significance

The Expression and Clinical Significance of Vascular Endothelial Growth Factor-C in Gastric Cancer Tissues

The expression and clinical significance of Survivin and VEGF in renal cell carcinoma

[Expression of Hypoxia-Inducible Factor-1-alpha, Hypoxia-Inducible Factor-2Alpha and Vascular Endothelial Growth Factor in Sporadic Clear Cell Renal Cell Renal Cell Carcinoma and Their Significance in the Pathogenesis Thereof].

Expression and significance of VEGF and PCNA in renal cell carcinoma

Identification of Novel Proteins Interacting with Vascular Endothelial Growth Inhibitor 174 in Renal Cell Carcinoma.

The clinical significance of vasculogenic mimicry and expression of VE-cadherin in patients with clear cell renal cell carcinoma

Expression of GLUT1 and VEGF in renal cell carcinomas and their clinical significance meanings

Abstract 1356: Vascular Endothelial Growth Inhibitor - Potential Role in Targeted Therapy in Kidney Neoplasma Via Angiogenic Inhibition

Expression and clinical significance of Survivin and Vimentin in clear cell renal cell carcinoma

Expression of vimentin in renal cell carcinoma tissue and its clinical significance

Expression of Vascular Endothelial Growth Inhibitor (VEGI) in Human Urothelial Cancer of the Bladder and Its Effects on the Adhesion and Migration of Bladder Cancer Cells in Vitro.